Activation of the MEK-S6 pathway in high-grade ovarian cancers

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 6, 2010, Pages 499-508

  Ventura, Aviva P ^a   Radhakrishnan, Sabarinath ^a   Green, Ann ^a   Rajaram, Sunitha K ^a   Allen, April N ^a   O'Briant, Kathy ^a   Schummer, Michèl ^a   Karlan, Beth ^b   Urban, Nicole ^a   Tewari, Muneesh ^a   Drescher, Charles ^a   Knudsen, Beatrice S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

AKT; MEK; ovarian cancer; pathway activation; S6

Indexed keywords

BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RIBOSOME PROTEIN; S6 KINASE;

ARTICLE; ASCITES; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ASCITES; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE KINASES; OVARIAN NEOPLASMS; OVARY; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78650512598     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181e53e1c     Document Type: Article

References (45)

1. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41-44. (Pubitemid 38018236)
2. Stordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007;33:688-703. (Pubitemid 350089290)
3. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167-181.
4. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64: 7678-7681. (Pubitemid 39446895)
5. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/ threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992;89:9267-9271.
6. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000; 19:2324-2330. (Pubitemid 30307208)
7. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151-160.
8. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009; 69:4036-4042.
9. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174: 1597-1601.
10. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005; 11:2875-2878. (Pubitemid 40525186)
11. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90:378-381. (Pubitemid 36952030)
12. Geyer JT, Lopez-Garcia MA, Sanchez-estevez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol. 2009;33:1157-1163.
13. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486. (Pubitemid 36432423)
14. Nakayama N, Nakayama K, Yeasmin S, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 2008;99:2020-2028.
15. Nicosia SV, Bai W, Cheng JQ, et al. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am. 2003;17: 927-943. (Pubitemid 37022149)
16. Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15:4649-4664.
17. Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33:392-406. (Pubitemid 44142735)
18. Yacoub A, Gilfor D, Hawkins W, et al. MEK1/2 inhibition romotes Taxotere lethality in mammary tumors in vivo. Cancer Biol Ther. 2006;5:1332-1339. (Pubitemid 44772260)
19. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-3310. (Pubitemid 46763022)
20. Cobb MH, Xu S, Hepler JE, et al. Regulation of the MAP kinase cascade. Cell Mol Biol Res. 1994;40:253-256. (Pubitemid 24349814)
21. Rossomando AJ, Payne DM, Weber MJ, et al. Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated erine/ threonine protein kinase. Proc Natl Acad Sci U S A. 1989;86: 6940-6943.
22. Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol. 1996;8: 402-411. (Pubitemid 26229663)
23. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9:747-758.
24. Flotow H, Thomas G. Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver. J Biol Chem. 1992; 267:3074-3078.
25. Ferrari S, Bandi HR, Hofsteenge J, et al. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem. 1991;266:22770-22775. (Pubitemid 21908714)
26. Nakayama K, Nakayama N, Kurman RJ, et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 2006;5:779-785. (Pubitemid 44775134)
27. Noske A, Kaszubiak A, Weichert W, et al. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett. 2007;246:190-200. (Pubitemid 44959391)
28. Samouelian V, Maugard CM, Jolicoeur M, et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta- RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol. 2004;54:497-504. (Pubitemid 40022245)
29. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60: 1113-1117. (Pubitemid 35447590)
30. Gmyrek GA, Walburg M, Webb CP, et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol. 2001;159:579-590. (Pubitemid 32751088)
31. Armengol G, Rojo F, Castellvi J, et al. 4E-binding protein 1: a key molecular funnel factor in human cancer with clinical implications. Cancer Res. 2007;67:7551-7555. (Pubitemid 47281345)
32. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23: 5853-5857.
33. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/ eIF4E. Genes Dev. 2002;16:1472-1487. (Pubitemid 34686329)
34. Castellvi J, Garcia A, Rojo F, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006;107:1801-1811. (Pubitemid 44582949)
35. Chung J, Kuo CJ, Crabtree GR, et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992;69:1227-1236.
36. Shahbazian D, Roux PP, Mieulet V, et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006;25:2781-2791. (Pubitemid 43980385)
37. Plopper GE, McNamee HP, Dike LE, et al. Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. Mol Biol Cell. 1995;6:1349-1365.
38. Benedetti V, Perego P, Luca Beretta G, et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther. 2008;7:679-687. (Pubitemid 351482150)
39. Shannon AM, Telfer BA, Smith PD, et al. The mitogen-activated protein/extracellular signal-regulated kinase Kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. Clin Cancer Res. 2009; 15:6619-6629.
40. Wang Y, Van Becelaere K, Jiang P, et al. A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia. 2005;7:336-347. (Pubitemid 40664223)
41. Jin N, Jiang T, Rosen DM, et al. Dual inhibition of mitogenactivated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94:4107-4112.
42. Lauchle JO, Kim D, Le DT, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive ras. Nature. 2009; 461:411-414.
43. Hsu CY, Bristow R, Cha MS, et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin ancer Res. 2004;10:6432-6436. (Pubitemid 39346537)
44. Daouti S, Wang H, Li WH, et al. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy. Cancer Res. 2009;69: 1924-1932.
45. Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009;69:6839-6847.